臺灣地區查獲之MDMA和Ketamine毒品分析

Analysis of MDMA and Ketamine Sample Seizures in Taiwan

10.6288/TJPH2005-24-03-11

莊淑棻(Shu-Fen Chuang)；吳守謙(Shou-Chien Wu)；蔡文瑛(Wen-Ing Tsay)；李志恒(Jin-Heng Li)；劉瑞厚(Ray H Liu)；柳如宗(Ju-Tsung Liu)；李天濬(Tien-Chun Lee)；楊易達(Yi-Ta Yang)；孫曼蘋(Main-Ping Sun)

搖頭丸 ； 愷他命 ； N-甲基－3，4亞甲基雙氧甲基安非他命 ； 緝獲物 ； MDMA ； Ketamine ； DMMDA ； Arrested

台灣公共衛生雜誌

24卷3期（2005 / 06 / 01）

264 - 273

繁體中文

目標：探討1998年至2003年臺灣地區查獲MDMA和ketamine毒品之件數、劑量及使用趨勢。方法：收集臺灣地區司法、檢警、衛生相關檢驗實驗室之MDMA和ketamine毒品檢驗案件數及檢體劑量數資料，分析濫用趨勢，並探討緝獲檢體之外觀特性、所含成分及不純物。結果：1998年至2003年期間臺灣地區緝獲檢出MDMA及ketamine相關檢體案件數計有12,941件，其中於2000至2001年開始明顯增加，2001年的MDMA案件數696件，沒收212,820件檢體。2002年MDMA和ketamine毒品濫用檢體件數急速攀昇。以緝獲MDMA和Ketamine檢體案件數比較，緝獲件數由2001年的936件，遽增至2002年的7,311件。緝獲錠劑除有特殊文字、圖案外，併用其他成分，如caffeine、methamphetamine、cannabis、tramadol、FM2、phenobarbital等，亦有增加之趨勢。另亦測到MDMA錠劑內含不純物如DMMDA、MDP和N-methyl-1-(3,4-methylenedioxy) benzylamine，而MDEA或MBDB則未測到。結論：臺灣地區在1998年至2003年期間所緝獲檢出MDMA及ketamine相關毒品案件數，2002年達濫用最高點，雖MDMA毒品在2003年有輕微下降，但ketamine毒品確仍維持持續上揚，整體的濫用毒品均為上昇趨勢。

Objectives: Confer the seizures, doses and use trends of seized MDMA and similar ketamine in Taiwan from 1998 to 2003. Methods: MDMA and ketamine drugs seized by the judicial, police and health sectors of Taiwan analyzed in government laboratories. The number of cases, appearance characteristics, and analysis of content and impurity data were used to characterize the abuse trend. Results: The number of arrest cases involving MDMA and ketamine in Taiwan was 12,941 in the period from 1998 to 2003. The number of arrested cases had clearly grown in the period from 2000 to 2001. In 2001, the number of arrested MDMA cases was at least 696 and the total number of forfeited samples was 212,820. In 2002, the number of sampled cases of the abuse of MDMA and ketamine drugs had rapidly grew. Compared with the arrested MDMA and ketamine sample cases, the arrested number had rapidly grown from 936 in 2001 to 7,311 in 2002. The seized tablets had particular words and pattern. Besides, the number of tablets which were mixed with other components such as caffeine, methamphetamine, cannabis, tramadol, FM2, phenobarbital and etc had grown. Furthermore, we had also detected that tablets of MDMA contained impure components such as DMMDA, MDP and N-methyl-1-(3,4-methylenedioxy) benzylamine. However, we did not detect any MDEA and MBDB component in confiscated samples. Conclusions: The number of MDMA and ketamine drugs from the drug seizures has risen since 1998, indicating that the trend of drug abuse is on the increase, although the amount of MDMA detected declined in 2003.

1. German National Report, 2002. Drug Markets: Seizures
2. Federal Register July 13, 1999 (Volume 64, Number 133). Placement of ketamine-into schedule Ⅲ: Scheduling Actions-1999. (cited 2004 May 10)
3. Annual Report 2003: the State of the Drugs problem in the European Union and Norway. Markets and availability: Markets-l0(i)
4. National Forensic Labortory Information System. Annual Report, 2001. Drug Cases Analyzed. (cited 2004 May 10) Available from
5. Annual Report 2003: the State of the Drugs Problem in the European Union and Norway Markets and availability: Markets-q(i)
6. Finland Nation Report, 2002. Drug Markets: Seizuares
7. Drug Cases Analyzed (cited 2004 May 10)
8. Altura BT,Altura BM.(1984).Effects of barbiturates, phencyclidine, ketamine and analogs on cerebral circulation and cerebrovascular muscle.Microcirc Endoth Lym,1,169-84.
9. Antoniou T,Tseng AL.(2002).Interactions between recreational drugs and antiretroviral agents.Ann Pharmacother,36,1598-613.
10. Brenneisen RL., Salamone SJ(2001).Pharmacology of flunitrazepam and other benzodiazepines.Benzodiazepines and GHB Detection and Pharmacology,12
11. Byrd LD,Standish U,Howell LL.(1987).Behavioral effects of phencyclidine and amphetamine alone and in combination with other drugs.Eur J Pharmacol,144,331-41.
12. Cheng WC,Poon NL,Chan MF(2003).Chemical profiling of 3, 4-3, 4-methylenedioxymethamphetamine (MDMA) tablets arrested in Hong Kong.J Forensic Sci,48,1249-59.
13. Dal Carson TA.(1990).An evaluation of the potential for clandestine manufacture of 3, 4-(methylenedioxy) amphetamine (MDA) analoys and homologs.J Forensic Sci,34,675-97.
14. Drug Enforcement Adiministration(1999).Uncommon precursor Sources used in 3, 4-methylenedioxymethamphetamine (MDMA).Microgram,32,193-4.
15. Freese TE,Miotto K,Reback CJ.(2002).The effects and consequences of selected club drugs.J Subst Abuse Treat,23,151-6.
16. Gowing LR,Henry-Edwards SM,Irvine R,Ali RL(2002).The health effects of ecstasy: a literature review.Drug Alcohol Rev,21,53-63.
17. Green AR,Mechan AO,Elliott JM,O'shea E,Colado MI.(2003).The pharmacology and clinical pharmacology of 3, 4-methylenedioxymethamphetamine (MDMA, “ecstasy”).Pharmacol Rev,55,463-508.
18. Iwanami A,Kanamori R,Suga I,Kaneko T,Kamijima K.(1995).Reduced attention-related negative potentials in methamphetamine psychosis.J Nerv Ment Dis,183,693-7.
19. Kojima T,Matsushima E,Nakajima K(1990).Eye movements in acute, chronic, and remitted schizophrenics.Biol Psychiat,27,975-89.
20. Laing RR,Dawson B.(1997).Identification of the major product from the Ritter reaction using safrole.J Clan Lab Invest Chem,7,22-6.
21. Lock E.(1997).Impurities found in MDMA and MDEA street samples: synthesis, identification and interpretation.Proceedings of the ENFSI 1st European Meeting of Forensic Science,17-9.
22. Matsushima E,Kojima T,Ohta K(1998).Exploratory eye movement dysfunctions in patients with schizophrenia: possibility as a discriminator for schizophrenia.J Psychiat Res,32,289-95.
23. Merck E.(1914).Verfahren zur darstellung von alkyloxyaryl-, dialyloxyary-, und alkylenedioxyaryaminopropanen, bzw.Deren armistickstoff monalkylierten deriveaten,274,350.
24. Micallef J,Tardieu S,Gentile S(2003).Effect of a subanaesthetic dose of letamine on emotional an behavioral state in healthy sufjects.Neurophysiol Clin,33,138-47.
25. Mikami T,Naruse N,Fukura Y(2003).Determining vulnerability to schizophrenia in methamphetamine psychosis using exploratory eye movements.Psychiat Clin Neuros,57,433-40.
26. NIDA Community Epidemiology Work Group(2003).Epidemic Trends in Drug Abuse volume 1.Division of Epidemiology, Services and Prevention Research, National Institute on Drug Abuse
27. O’ Connell D,Haffron JJA.(2000).Rapid analysis of illicit drugs by mass spectrometry: results from seizures in Ireland.Analyst,125,119.
28. Poortman A.(1998).Unusual manufactureing of MDMA in The Netherlands.J Clan Lab Invest Chem,8,25-6.
29. Renton RJ,Cowie JS,Oon MCH.(1993).A Study of the precursors, intermediates and reaction by-products in the synthesis of 3, 4-methylenedioxymethamphetamine and its application to forensic drug analysis.Forensic Sci Int,60,189-202.
30. Rochester JA,Kirchner JT(1999).Ecstasy (3, 4-methylenedioxymethamphetamine): history, neurochemistry, and toxicology.J Am Board Fam Pract,12,137-42.
31. Sato M,Numachi Y,Hamamura T.(1992).Relapse of paranoid psychotic state in methamphetamine model of schizophrenia.Schizophrenia Bull,18,155-22.
32. Smith KM,Larive LL,Romanelli F.(2002).Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate.Am J Health-Sys Ph,59,1067-76.
33. Stein D.(1996).The use of heliotrope nil as a precursor source for piperonal.J Clan Lab Invest Chem,6,17-8.
34. Teter CJ,Guthrie SK.(2001).A comprehensive review of MDMA and GHB: two common club drugs.Pharmacotherapy,21,1486-513.
35. Traub SJ,Hoffman RS,Nelson LS.(2002).The “ecstasy” hangover: hyponatremia due to 3, 4-methylenedioxymethamphetamine.J Urban Health,79,549-55.
36. Verweij AMA.(1992).Impurities in Illicit drug preparations: 3, 4-(methylenedioxy) amphetamine and 3, 4- (methylenedioxy) methamphetamine.Forensic Sci Rev,4,137-46.
37. Vollenweider FX(1998).Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.Pharmacopsychiatry,31(2),92-103.
38. Walubo A,Seger D.(1999).Fatal multi-organ failure after suicidal overdose with MDMA, ‘ecstasy’: case report and review of the literature.Hum Exp Toxicol,18,119-25.
39. 行政院衛生署(2003)。92年8月藥物濫用案件檢驗統計資料。
40. 李偉華、蕭開平、鄭惠及(2002)。法醫解剖案例監測國內藥物流行趨勢及新興濫用藥物（一）。
41. 周碧瑟(1999)。臺灣地區在校生青少年藥物使用流行病學調查研究。行政院衛生署委託研究計畫(DOH88-TD-1064)。
42. 林錦雲、呂昀儒、楊子欣(2003)。2003物質濫用：物質濫用之防制、危害、戒治。273-84。
43. 林錦雲、莊淑棻(2003)。2003物質濫用：物質濫用之防制、危害、戒治。246-72。
44. 高百源、符永豐、張信男(2001)。揭開快樂丸的面紗。管制藥品簡訊，1，1-8。
45. 陳景宗、陳珮君、郭瓊林(2002)。安非他命與K他命(ketamine)的合併作用機轉研究。
46. 賴滄海(2001)。由尿液檢驗監測國內新興濫用藥物大麻、MDMA、FMZ等。

1. 關百娟、蔡麗紅、黃怡樺、涂慧慈、林昌明、沈昱名、史麗珠(2012)。台灣桃園地區中輟生成癮物質使用之路徑模式。學校衛生，61，103-126。
2. 賴香如、陳雯昭、張鳳琴、張瑜真、李碧霞、李景美、江振東(2008)。台北縣市高職學生開始使用成癮物質之危險與保護因子追蹤研究。臺灣公共衛生雜誌，27(5)，399-410。